Archives
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2018-07
-
Cy5 TSA Fluorescence System Kit The structures of these comp
2024-10-11

The structures of these compounds were confirmed from their spectral and micro analytical data. Based on [M + H] 367, molecular formula of was established as CHON. The IR spectrum of showed Cy5 TSA Fluorescence System Kit due to CO stretching at 1700 Cm & OH stretching at 3188 Cm indicating that
-
Furosemide Five alternatively spliced isoforms of ATX have b
2024-10-11

Five alternatively-spliced isoforms of ATX have been described and all are catalytically active [16], [17]. The original ATX described in 1992 is termed ATXα, whereas the most abundant isoform is ATXβ and is the same isoform responsible for plasma lysoPLD activity [18]. Full length ATX is synthesize
-
Several structural classes of ASK inhibitors mostly
2024-10-10

Several structural PDK1 inhibitor receptor of ASK1 inhibitors, mostly from industry but also from academia, have been identified over the last decade. In 2012, Terao et al. (Takeda) reported imidazo[1,2-α]pyridine () as a potent ASK1 inhibitor derived from structure-based drug design. GSK, Merck and
-
ttp stock mg br Materials and methods br Results In order to
2024-10-10

Materials and methods Results In order to evaluate changes in the amount of PKC-θ expressed by MEL cells at different stages of the cell cycle, we measured the level of the kinase in cells collected from cultures containing 90% of cells in the interphase or 80% cells synchronized at the metaph
-
The current antifungal pipeline contains several categories
2024-10-10

The current antifungal pipeline contains several categories of compounds at different stages of development [1], [9], [10], [96]. In Table 1 we summarize the most promising antifungal molecules that are in preclinical and in clinical development. Several compounds in the pipeline are derivatives of
-
Tumor tissues often experience hypoxia owing to
2024-10-10

Tumor tissues often experience hypoxia owing to accelerated growth rates of malignant cells, accumulation of metabolic products, disorganization of tumor blood vessels, and high interstitial fluid pressures (Makino et al., 2001). In response to AAD treatment, tumor vascular density often decreases t
-
The increased occurrence of ARIA E in APOE carriers
2024-10-10

The increased occurrence of ARIA-E in APOE ε4 carriers in phase 2 studies resulted in separate protocols for carriers and noncarriers in the subsequent phase 3 studies. Two 18-month trials comprising 1121 carriers and 1331 noncarriers with mild to moderate AD tested doses of bapineuzumab that varied
-
br Perspective AA LA and other
2024-10-10

Perspective AA, LA and other PUFAs and their lipid metabolites play an important role in human diseases. 12/15-LOX which is the metabolic enzyme of them plays an important role in the pathogenesis-related diseases such as atherosclerosis, diabetic nephropathy, neurological diseases and other path
-
br Discussion The patient presented initially only with pari
2024-10-10

Discussion The patient presented initially only with parietal symptoms in the form of acalculia, visuo-spatial deficits, and visuo-perceptual deficits and dressing apraxia. He also had simultognosia as early symptoms. Later when the disease progressed he had recent memory deficits and language in
-
For the first series we
2024-10-10

For the first series we decided to verify the effects induced, on the ALR2 inhibitory properties, of an additional steric hindrance on the carbon in α position with respect to the carboxylic group, by introducing a methyl group (R2=Me). Therefore, we synthesized a series of new α-alanine derivatives
-
The rank order of agonist potency in turkey cardiac
2024-10-10

The rank order of agonist potency in turkey cardiac chambers demonstrated the predominant presence of the β-adrenergic receptor subtype, in line with the receptor classification by . However, a previous radioligand binding study in the left ventricles of 7-week old turkeys reported the existence of
-
PX 866 The next level of possible correlation and comparison
2024-10-09

The next level of possible correlation and comparison between the α7 and 5HT3 receptors is at the subunit arrangement and protein folding. Crystal structures of the nicotinic and serotoninergic PX 866 receptors [45], [46] reinforced the concept of similarities between these families of receptors. N
-
br Materials and methods br Results br Discussion Prostate c
2024-10-09

Materials and methods Results Discussion Prostate cancer represents an ideal candidate for chemoprevention because of its high incidence and long latency to clinically significant disease [17]. The precancerous lesion PIN may also be a suitable target for ablation in chemoprevention strateg
-
Signaling through Axl can lead to activation
2024-10-09

Signaling through Axl can lead to activation of the PI3K/Akt and Ras/MAPK pathways which promote cellular phenotypes (e.g., transformation, migration) consistent with pro-survival and pro-metastatic effects., , Inhibition of Axl activity by a variety of approaches (including pharmacologic, dominant
-
In conclusion AXL overexpression preexisted in
2024-10-09

In conclusion, AXL overexpression preexisted in a subgroup of treatment-naive lung adenocarcinoma specimens harboring an activating EGFR mutation or in those with wild-type EGFR. Anti-AXL therapeutics delivered up front in combination with the EGFR inhibitor might overcome intrinsic or acquired resi
15707 records 97/1048 page Previous Next First page 上5页 96979899100 下5页 Last page